Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK610677
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
GSK610677 is an investigational inhaled therapy developed by GSK (formerly GlaxoSmithKline) for the treatment of chronic obstructive pulmonary disease (COPD). It has been studied in phase I clinical trials to assess its safety and tolerability in escalating single inhaled doses. The precise mechanism of action for GSK610677 remains undefined, and it is classified broadly as an antiasthmatic agent. As of the latest available information, there have been no recent reports of further development or advancement beyond early-phase clinical studies[1][2][4].
- Other names
- GSK 610677GSK610677GSK-610677610677
Beyond the preview
Go deeper on GSK610677.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK610677.